Clinical trial
A 12-Month Open Label Safety Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR®) in Children Ages 4-5 Years Diagnosed With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT02677519 is registered in ClinicalTrials.gov with Rhodes Pharmaceuticals, L.P. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 12-Month Open Label Safety Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR®) in Children Ages 4-5 Years Diagnosed With Attention-Deficit/Hyperactivity Disorder (ADHD)
- Lead sponsor
- Rhodes Pharmaceuticals, L.P.
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- September 30, 2016
- Completion date
- September 30, 2017
- Enrollment
- 120 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.